Immunomedics 8-K 2008
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
Date of Report (Date of earliest event reported) July 11, 2008
Registrant's telephone number, including area code: (973) 605-8200
Item 1.01. Entry into a Material Definitive Agreement.
On July 11, 2008 (the "Execution Date"), Immunomedics, Inc., a Delaware corporation (the "Company") entered into a License and Collaboration Agreement (the "Agreement") with Nycomed GmbH ("Nycomed") providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, the Company's humanized anti-CD20 antibody ("Veltuzumab") in the subcutaneous formulation, for the treatment of all non-cancer indications. The Company retains the rights to develop, manufacture and commercialize Veltuzumab in the field of oncology.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. 99.1 Press Release of Immunomedics, Inc. dated July 14, 2008.
99.1 Press Release of Immunomedics, Inc. dated July 14, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.